Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

Sunitinib (SU11248) is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vascular endothelial growth factor (vegf) receptors 1, 2, 3, and platelet-derived growth factor receptors alpha (pdgfra) and beta (pdgfrb)....

Full description

Saved in:
Bibliographic Details
Main Authors: Buckstein, R., Meyer, R.M., Seymour, L., Biagi, J., MacKay, H., Laurie, S., Eisenhauer, E.
Format: Artigo
Language:Inglês
Published: Multimed Inc. 2007
Subjects:
Canadian Centre Activities
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1948864/
https://ncbi.nlm.nih.gov/pubmed/17710208
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items